Great news!! Congratulations and looking forward to the results👏👏

1/ New thread summarising the recently published NDT paper by YNP of ERA author Manuel Anderegg 🇨🇭 Link to paper 👉academic.oup.com/ndt/article/39… 🧵by Kaitlin Mayne ERA - European Renal Association Hans-Joachim Anders

SGLT-2 inhibitors - approved for cats, but not (yet) for children... Time for a change! Here comes DOUBLE PRO-TECT with Prof. Dr. Oliver Groß and special guest 𝐉𝐨𝐬𝐞𝐩𝐡 𝐅𝐥𝐲𝐧𝐧, 𝐌𝐃 Andreas Kronbichler NDT Hans-Joachim Anders's NDT pick of the month! youtu.be/L8QYSe0ujoM?si… via YouTube

Thank you Samir! great timing with the video..😃

Awaiting Daniel G. Fuster's interventional SWEET STONE trial: Here comes more epidemiological data that SGLT-2 may substantially lower the burden of nephrolithiasis - here studied in patients with prevalent stone disease Natalie McCormick Deutsche Gesellschaft für Nephrologie (DGfN) e.V. marcus_saemann bmj.com/content/387/bm…

Wonderful talk by Claude Chaussy in Bern on the history of ESWL urology-arena.ch/scientific-pro…

I’m delighted to welcome aboard an extraordinary scientist, leader, and mentor to ⁦UTSW Nephrology⁩ faculty today: Don Wesson’s community based research on nutrition and CKD brings his personal scientific journey from acidosis at the bench to the Dallas diaspora and beyond

Hoffnungsvolle Berner Nierenstein-Nachrichten: Das Diabetesmedikament Empagliflozin reduzierte in der von #InselGruppe & Universität Bern geleiteten SWEETSTONE-Studie die Nierensteinbildung deutlich. Mehr: inselgruppe.ch/de/aktuell/det… Daniel G. Fuster Manuel Anderegg Faculty of Medicine, University of Bern

Incredible data set published in Cell. Look at Figure 6F ! #suPAR 👇👇 Atlas of the plasma proteome in health and disease in 53,026 adults: Cell cell.com/cell/fulltext/…

Low BMD and fractures are common in kidney stone formers. HCTZ up to 50 mg daily did not preserve BMD compared to placebo over 3 years. Hydrochlorothiazide and Bone Mineral Density in Patients... : Clinical Journal of the American Society of Nephrology journals.lww.com/cjasn/abstract…

Just out in Nature Communications…..a mystery solved. It’s all about lipids in the regulation of intracellular NHEs. Thank you David for this great collaboration. rdcu.be/efxE2

Our new webinar in 🇩🇪🇦🇹🇨🇭🇱🇮 language: SGLT-2 Inhibitoren & Nierensteine: SWEETSTONE - Prof. D. Fuster, Prof. S. Trelle (Bern, Schweiz) WATCH NOW: youtu.be/i_YTcIQ4YQk?si… Daniel G. Fuster Gunnar Henrik Heine marcus_saemann

Patients with rare kidney diseases account for 5–10% of people with CKD, but make up > 25% of those receiving kidney replacement therapy. Addressing unmet needs for these patients could positively impact long term KRT demand. Read the full article: thelancet.com/journals/lance…

Dr Manuel Anderegg giving us the highlights of SWEETSTONE trial 🙌🏻 and the role of Empagliflozin in patients with calcium and acid uric stones. Remember, if you did not make it to a presentation, you can watch it on demand at ERA25 website. #era25 #beyondnephrology #ckd

✅Empagliflozin reduces urinary calcium and uric acid supersaturation in non-diabetic and non-CKD patients. The SWEETSTONE trial ⬇️ #ERA25 #beyondnephrology

Thank you Swiss National Science Foundation !! We just received 3.42 Mio CHF funding for our EMPASTONE trial. Looking forward to working with colleagues in Switzerland, Germany, France, Italy and the UK. clinicaltrials.gov/study/NCT06653…

🎉Herzliche Gratulation! Daniel Fuster #inselgruppe hat mit Lia Bally, Beat Roth, Andreas Christe & Eva Segelov einen #IICT-Grant des Schweizerischer Nationalfonds (SNF) erhalten für die EMPASTONE-Studie zur Prävention von #Nierensteinen mit Empagliflozin & Ernährungsberatung!👏 Faculty of Medicine, University of Bern Universität Bern